Author/Authors :
Yeganeh, Behzad University of Manitoba - Department of Physiology, Canada , Hashemi, Mohammad zahedan university of medical sciences - School of Medicine, Cellular and Molecular Research Center - Department of Clinical Biochemistry, ايران , Serres, Fredrick J. de Research Triangle Park - National Institute of Environmental Health Sciences, Center for Evaluation of Risks to Human Reproduction, USA , Los, Marek J. Linkoping University - Integrative Regenerative Medicine Center (IGEN) - Department of Clinical and Experimental Medicine, Division of Cell Biology, Sweden , Ghavami, Saeid Manitoba Institute of Child Health, Canada , Ghavami, Saeid University of Manitoba - Department of Physiology, Canada
Abstract :
Hepatocellular carcinoma (HCC) is considered as the third and also one of the most frequent global cancers, accounting for more than half a million deaths annually. There is a contentious rate in HCC incidence and mortality, which highlights the need for new and innovative therapeutic approaches. Over the last decade, the incidence of HCC remains the highest in Eastern Asia and Africa, while its frequency has grown progressively in western countries and in Japan as well.
Keywords :
Biological Markers , Alpha 1 Antitrypsin , lobaplatin , Aflatoxins , Hepatitis B Virus , Hepatitis C
